Multiparametric Response To Disease-Modifying Therapy For Transthyretin Amyloidosis Cardiomyopathy

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized condition with poor prognosis without treatment. The development of disease modifying therapies such as tafamidis has been shown to improve patient outcomes, but incorporation into clinical practice has been slow due in part to cost and lack of access. Targeting therapy to those experiencing the greatest benefit may help to alleviate these barriers to care, although indicators of a beneficial response to tafamidis has not been clearly defined.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 110 Source Type: research